ENDRA Life Sciences Mourns the Passing of Board Member Sanjiv Gambhir
Back to Newsroom
Mentioned in this Article

ENDRA Life Sciences Mourns the Passing of Board Member Sanjiv Gambhir

Thursday, July 23, 2020 4:00 PM
Share this article now
Company Update

ANN ARBOR, MI / ACCESSWIRE / July 23, 2020 / ENDRA Life Sciences Inc. (''ENDRA'') (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®) is mourning the loss of Sanjiv "Sam" Gambhir, M.D, Ph.D, a member of ENDRA's Board of Directors, who passed away July 18, 2020.

Since 2011, Dr. Gambhir served as Chair of Radiology at Stanford University School of Medicine. He was a clinician and scientist at the forefront of molecular imaging and cancer detection and had served on ENDRA's board since 2008.

"I am deeply saddened by Dr. Gambhir's passing. Sam was a rare combination of scientific brilliance and intensity wrapped in a modest and approachable demeanor. Sam was also at the core of ENDRA's beginnings and progress to our current state," said Francois Michelon, CEO of ENDRA. "Sam coalesced the first members of ENDRA's board and stayed actively engaged as a board member until the very end," continued Michelon.

"ENDRA benefitted from Sam's deep healthcare expertise and vision that ENDRA's disruptive technology could broaden access to better healthcare for billions of patients worldwide. Our thoughts and prayers remain with Sam's wife, and all of the extended Gambhir family," concluded Michelon.

No changes are anticipated to day-to-day business activities and the Company remains committed to making Sam's vision a reality, as commercialization begins this year for the first clinical application of TAEUS.

About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to visualize tissue like an MRI, but at 1/50th of the cost, at the point of patient care. TAEUS is designed to work in concert with existing ultrasound systems. TAEUS is initially focused on the measurement of fat in the liver, as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect over 1 billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures. www.endrainc.com

Forward-Looking Statements
All statements in this release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "goal," "estimate," "anticipate" or other comparable terms. Examples of forward-looking statements include, among others, statements we make regarding expectations regarding the commercialization and sales of our TAEUS device in European jurisdictions, obtaining U.S. 510(k) regulatory approval for our TAEUS device and the timing of any such approval; plans relating to our supply chain and clinical studies of the TAEUS device, including its adoption by clinicians; and expectations concerning ENDRA's product development and business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including, among others, the following: our ability to develop a commercially feasible technology; receipt of necessary regulatory approvals; the impact of the COVID-19 pandemic on our business strategy; our ability to find and maintain development partners, market acceptance of our technology, the amount and nature of competition in our industry; our ability to protect our intellectual property; and the other risks and uncertainties described in ENDRA's filings with the Securities and Exchange Commission. The forward-looking statements made in this release speak only as of the date of this release, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.

Company Contact:
David Wells
Chief Financial Officer
(734) 997-0464
[email protected]

Media Relations Contact:
Denise DiMeglio
(610) 228-2102
[email protected]

Investor Relations Contact:
Joe Hassett
(484) 686-6600
[email protected]

SOURCE: ENDRA Life Sciences Inc.

ENDRA Life Sciences Inc.
Back to Newsroom
Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |  Terms and Conditions
Drop us a line: